Abstract. This study evaluates cross-immunity in rhesus monkeys (Macaca mulatta) previously infected with one species of Leishmania and have had self-cured disease or were cured by antimony-based therapy upon development of full-blown disease. We found that a self-healing cutaneous leishmaniasis ( 
INTRODUCTION
Leishmaniasis is one of the major parasitic diseases target by the World Health Organization. The genus Leishmania Ross, 1903 (Kinetoplastida: Trypanosomatidae) includes approximately 30 different species that are classified in two subgenera, Leishmania and Viannia, 1 and each of these parasites has a unique epidemiologic pattern. These data explain the limited success of current control strategies based on conventional measures (such as vector reduction and elimination of infected reservoirs) for American leishmaniases. In addition, the containment of the disease is complicated by the fact that 1) many of the Leishmania species causing human illness readily acquire resistance to antimonial drugs and 2) response to treatment varies considerable depending on the parasite strain involved and the clinical form. 2 The protective immunity observed following convalescence for cutaneous leishmaniasis (CL) or visceral leishmaniasis (VL) 3, 4 has suggested that vaccination may prove to be the most cost-effective intervention method for the control of the various leishmanial infections. Research into the development of safe and effective vaccines against the disease has been encouraged by reports of cross-protection between distinct, though by no means all, Leishmania species (Table 1) . Cross-immunity experiments between different strains of Leishmania may give important clues as to the most suitable parasites for use in antigen production to protect against the disease. Vaccines consisting of viable or killed forms of the pathogen itself have been evaluated with CL. [3] [4] [5] While the use of murine models have improved our understanding of the factors involved in heterologous protection, [6] [7] [8] [9] the mechanisms behind this acquisition of immunity remain obscure. Whereas the taxonomic identity of the parasites plays a role in the degree of cross-reactivity, genetically determined susceptibility or resistance of the host may be equally influential in the development of a protective immunity. 10 Nonhuman primates appear to have significant advantages over conventional laboratory animals in terms of modeling human leishmaniasis (in particular reference to infection induced with L. braziliensis complex parasites) [11] [12] [13] for purposes of studies on cross-immunity between different species or strains of Leishmania. A few experiments of this nature have been carried out in monkeys, [14] [15] [16] [17] but have not clarified this situation.
In our previous studies, the rhesus monkey (Macaca mulatta) was found to be readily infected with either 19 This primate model develops a human-like disease (namely, a selfhealing chronic granulomatous CL and resistance to homologous challenges), exhibits antibodies to Leishmania and parasite-specific T cell-mediated immune responses, and can be protected effectively by Leishmania vaccination. 20, 21 We also found that primary L. (L.) chagasi infection of the rhesus monkey appears to parallel the human responses to infection, including the development of strong immunity to reinfection with the homologous parasite (Pereira MS and others, unpublished data).
The purpose of this study was to potentially examine crossreacting immune responses and possible cross-protection between taxonomically distinct leishmanial parasites in this experimental model. This finding is important for vaccine development studies against leishmaniasis.
MATERIALS AND METHODS

Animals.
A total of 38 laboratory-bred and -reared young adult (3−10 years old, weighing between 4,100 and 14,650 grams) rhesus macaques of mixed sexes were used in this study. Thirty-four of the animals had been previously infected with either L. (L.) major, 19 L. (V.) braziliensis, 13 or L. (L.) chagasi (Pereira MS, unpublished data), but had recovered from clinical disease (following either self cure or therapeutic intervention) by the time of each re-challenge. The other four monkeys were naive controls that had never been exposed to Leishmania antigens. Their care and maintenance have been previously described. 18 All procedures involving animals were performed according to the Brazilian Guide For Care The strains were typed by multilocus enzyme electrophoresis 22 in our laboratory before being used for infection. Parasites were maintained by hamster-to-hamster passage. The procedure for parasite derivation for experimental infections 18 Suspensions of promastigotes were used throughout, and the parasites were derived from portions of hamster skin lesions cultured initially in NNN blood agar medium. When promastigotes appeared, the parasites were inoculated into liquid Schneider's Drosophila medium (GIBCO-BRL, Gaithersburg, MD) supplemented with 20% heat-inactivated fetal calf serum (FCS), and passaged no more than three times before use for needle inoculation. Culture metacyclics were harvested by centrifugation at 1,500 × g for 10 minutes at 4°C. The pellets were washed three times in sterile phosphate-buffered saline (PBS) by centrifugation as reported. Stocks of infective metacyclics derived from each parasite species were stored as stabilates at -190°C in liquid nitrogen containers using 8% glycerol in Schneider's medium containing 30% FCS. This study was divided into three experiments. An infection profile of the monkeys and number of animals used for each cross-immunity trial is shown in Table 2 . Groups of animals were challenged at different time points after they had recovered from either CL (groups A-F) or VL (group G). Primates were inoculated with 10 7 stationary phase promastigotes of each heterologous parasite either into the skin of the opposite eyebrow or forearm, depending on the site of the original inoculation. Groups of two naive controls were similarly infected with either L. (V.) guyanensis or L. (V.) panamensis for determining the progression and resolution of primary skin lesions induced by each parasite in rhesus monkeys. In addition, two control hamsters were in each case inoculated to check viability of the parasites. Skin lesions were measured with a vernier caliper and lesion size was estimated using the following formula: area (mm 2 ) ‫ס‬ × greatest radius × smallest radius.
Antigens
were the source of antigens. A preparation of soluble leishmanial antigens (SLA) was made as previously described. 19 The SLA was used at different concentrations for an enzyme-linked immunosorbent assay (ELISA) and in vitro blast transformation assays.
Assessment of delayed-type hypersensitivity (DTH) responses. Animals were assessed for DTH reactions according to the method used for humans (leishmanin skin test [LST] ). The antigen (leishmanin), provided by the FIOCRUZ Biomanguinhos Unit (Rio de Janeiro, Brazil), consisted of pooled, heat-killed, cross-species promastigotes suspended in PBS containing 0.5% phenol. For the LST, 0.1 mL of antigen containing macromolecules from 5 × 10 6 parasites was inoculated intradermally into the forearm, and the induration produced was measured in millimeters 72 hours later. An induration diameter Ն 5 mm was considered positive.
Assessment of recall proliferative and interferon-␥ (IFN-␥) responses.
The cellular immune responses were studied in vitro by lymphocyte proliferative assays with SLA (10 g of protein/well) and mitogen (phytohemagglutinin [PHA] from 
L. guyanensis, L7 Complete * Number of animals used in each experiment. † The stock codes of the strains used in this study are indicated and information on their origin is given elsewhere (Materials and Methods). ‡ Monkeys were rechallenge-infected after they had recovered from previous (primary, secondary, and/or terciary) infection(s). In some experiments, animals were injected with the same parasite strain/dose, but at different time points as indicated (at 28 ¶ and 44# weeks postinfection).
§ Acquired immunity to Leishmania in tested monkeys was measured by the level of clinical resistance to each rechallenge: complete protection, animals were refractory to the disease (i.e., no lesion observed); partial protection (i.e., individuals developed a transient lesion with smaller size that healed faster than in the primary infection); or lack of protection (i.e., monkeys remained susceptible to re-infection).
Phaseolus vulgaris, 12.5 g/mL; Sigma, St. Louis, MO). 18 Cell proliferation was expressed as a stimulatory index (SI) and was considered positive if > 2.5. The IFN-␥ in supernatants of cultures of stimulated cells were measured by an ELISA as previously described. 13 A rhesus monkey IFN-␥ ELISA kit was used following the manufacturer's instructions (Biosource International, Camarillo, CA). The IFN-␥ concentrations for unknown samples and controls were read from a standard curve.
Serologic analysis. Sera from the monkeys were analyzed by adapting a standard ELISA 18 to detect parasite-specific antibodies (using a peroxidase-conjugated rabbit antimonkey IgG; Sigma). A group of sera with previously known titers, as well as naive rhesus controls, were included in each test.
Statistical analysis. The Student's t-test was used for comparative analysis and a P value < 0.05 was considered significant. Concordance between in vivo and in vitro cellular immune responses was assessed as previously reported. 19 
RESULTS
Primates challenge infected with the different leishmanias (experiment 1) were kept under observation (we allowed a period of 3−6 months to elapse before judging the heterologous challenge result as negative). Subsequent challenges (experiments 2 and 3) were done after the complete disappearance of any resulting skin lesion (in this case, the time required for recovery varied from approximately one week to as long as six months). Acquired immunity to Leishmania was then measured by the level of clinical resistance to each challenge, as indicated in Table 2 
(V.) guyanensis (group C), but it failed to confer immunity to L. (V.) braziliensis (group D). Two control naive monkeys received a similar dose of L. (V.) guyanensis and both animals became infected (the nodular lesions that developed were up to 1 cm in diameter at the site of inoculation, ulcerated, and slowly disappeared during the six month after infection). In contrast, L. (L.) chagasi infection in the rhesus monkey induced a strong resistance to re-infection with L. (V.) braziliensis (group G)
. Similarly, monkeys previously exposed to infection with either the L3 (group E) or L4 (group F) strain of L. (V.) braziliensis were completely immunized against challenge with an homologous parasite (strain L5) that represented a distinct genotype.
13
Course of tertiary and quaternary infections. As shown in Table 2 Figure  4 . Peripheral blood leukocytes of animals were comparably responsive to the control mitogen PHA prior to and after challenges. The parasite-specific lymphocyte proliferative responses were negative (SI < 2.5) in primates prior to infection, and following primary and challenge infections, these animals exhibited proliferative and IFN-␥ responses of peripheral blood leukocytes to leishmanial antigens. The findings indicated that in L. (V.) braziliensis-infected monkeys (group F), no significant difference was observed between the SI mean values throughout infection, but the levels of antigen-specific IFN-␥ secreted were lower after the homologous challenge compared with the levels during the primary infection. In spite of wide variations from one infected animal to another (as shown by some large SD values), following the heterologous challenge, there was a statistically significant difference (P < 0.05) in the recall cell-mediated immune responses to the L. major and L. braziliensis antigens ( Figure 4B ). In addition, infected animals developed positive DTH responses; the pooled leishmanin antigen identified all monkeys with active 
DISCUSSION
Recovery from Leishmania infection in humans is generally thought to give rise to a long-lasting clinical resistance against homologous challenge.
3,4 However, some observations suggest that acquired immunity to homologous parasites may not always be complete. 23, 24 Studies in animal models (Table 1) show that acquired immunity to Leishmania conferred by experimental infection can protect against homologous challenge. For example, monkeys challenge infected with L. donovani have a lower burden of parasites in their livers than can be found following primary infection with the same parasite strain. 25 Similar results were obtained in other primate models for CL. 14, 15, [26] [27] [28] Unfortunately, in most studies of this nature it is difficult to accurately assess partial host immunity during infection since skin lesion size, a highly variable parameter, is commonly used as indication of protection.
A self-healing phenomenon in experimental murine leishmaniasis is indicative of the development of acquired immunity. Protective immunity to Leishmania seems to require the development of a antigen-dependent Th1 immune response. 29 Studies with the vervet monkey model for L. (L.) major CL indicated that antigen-specific IFN-␥ and DTH responses represent immunologic correlates of protection. 26 However, sensitization to the infection and/or the duration of the elicited immune responses, and their roles in acquired immunity, may vary in certain host-parasite combinations. 30 Our findings indicate that parasite-specific type 1 responses develop in either L. (L.) major-or L. (V.) braziliensisinfected monkeys, but the levels of T cell proliferative and IFN-␥ responses and/or LST response do not always correlate with recovery from the skin lesions. 3, 19 This was also the situation in vaccinated monkeys, in which neither positive DTH reactions nor increased production of IFN-␥ were predictive of protection. 20, 31 This fact raises a question on the current parameters that should be considered as a counterpart of expected protection induced by vaccine.
Whether the intensity of duration of the elicited responses and their roles in immunity may vary according to the nature of the infecting parasite strain or the genetic variability of the host remains to be established in the rhesus model. The experiments reported here show that following the resolution of an induced L. (V.) braziliensis CL, 13 the rhesus monkey consistently develops immunity against homologous parasites (experiment 1, groups E and F), although the level of acquired resistance may be variable depending on the infecting strain (experiment 2, 2, group D). In contrast, monkeys that recovered from either L. (L.) amazonensis or L. (L.) major CL developed distinct levels of resistance (as reflected by either an absence of skin lesions or a smaller size and faster resolution of the lesions compared with the initial infection) to each homologous re-challenge. 18, 19 Therefore, the nature (i.e., etiologic agent) and the course of primary infection or disease tempo (i.e., the progression and resolution of leishmanial lesions) might influence protection. Similarly, vector factors also influence the evolution and outcome of CL. Infections from sand fly bites are more aggressive and require fewer parasites to initiate. The enhancing effect of sand fly saliva on CL has been demonstrated in rodents. 2 Moreover, culture metacyclics (the developmental stage of the parasite that is infective) are not as virulent as metacyclics isolated from sand flies. When infected with L. (L.) major transmitted by Phlebotomus papatasi, 33, 34 All infected animals responded with increased production of immunoglogulins capable of binding to cross-reacting parasite antigens. This is not surprising since the various species of Leishmania share a number of antigens. 35 The current study also indicates cross-reactivity at cellular levels between L. (L.) major and L. (V.) braziliensis in rhesus monkeys, but recall T cell type 1 responses did not correlate with heterologous protection ( Figure 4B ). These data suggest that much remains to be learned about what is required to develop and maintain cell-mediated immunity to leishmanial re-infections. Nevertheless, a high level of cellular cross-reactivity paralleled by cross-protection of L. (L) donovani against L. (L) major was shown in vervet monkeys. 16 More often, crossreactivity at cellular levels among leishmanias has been positively correlated with cross-immunity in mice. 36, 37 The relative variability in level of protection induced by experimental infection against subsequent challenges is probably due to several factors influencing the nature of immunity attained. One factor that can influence acquired protective immunity is the time between recovery from primary infection and re-challenge. For example, cross-immunity between L. (L.) major and L. (L.) amazonensis parasites in M. mulatta does not give rise to a long-lasting immunity against challenge. Groups of monkeys challenged with the same parasite strain/dose but at different time points (A ‫ס‬ 28 weeks and B ‫ס‬ 44 weeks) after the primary infection exhibited distinct level of protection. The biologic significance of this decrease in acquired resistance to subsequent challenge(s) is not clear, although those animals completely recovered and parasitefree would possibly develop lower resistance to re-infection. The long-term persistence of parasites in a host that is also able to maintain strong resistance to re-infection, referred to as premunition or concomitant immunity, may be the mechanism by which a sustained immunity to Leishmania is achieved in the infected host. 38, 39 Recent findings indicate that CD4 + CD25 + regulatory T cells control L. (L.) major persistence and immunity in murine experimental leishmaniasis. 39 The significance of these observations may be related to a leishmanial vaccine. Those living in endemic areas and therefore continuously exposed to the parasite would acquire life-long protective immunity to re-infection. Alternatively, a vaccine that can prevent the disease (but not the infection) would produce a strong priming so that continuous immunity would be achieved by repeated exposure to leishmanial parasites through the bites of infected sand flies. 40 Received April 9, 2003. Accepted for publication August 27, 2003. 
